9853 Pacific Heights Blvd.
Suite D. San Diego,
CA 92121, USA
Tel: 858-263-4982
Email: info@abeomics.com

30-2913: Anti-Hu CLEC2 APC Mab (AYP1)

Clonality :	Monoclonal
Clone Name :	AYP1
Application :	FACS
Reactivity :	Human
Conjugate :	APC
Gene :	CLEC1B
Gene ID :	51266
Uniprot ID :	Q9P126
Alternative Name :	CLEC1B, CLEC2B, PRO1384, QDED721
Isotype :	Mouse IgG1 kappa
Immunogen Information :	A recombinant extracellular domain of human CLEC2 (amino acids 68-229)

Description

Specificity: The mouse monoclonal antibody AYP1 recognizes an epitope within the extracellular part of CLEC2, a transmembrane glycoprotein expressed on activated plateles and on platelet microparticles.

CLEC2 (C-type lectin-like receptor 2) functions as a platelet receptor for the lymphatic endothelial marker, PDPN, and mediates platelet activation. Besides platelets, it can be found on myeloid cells and NK cells. CLEC2 functions also as an attachment factor for HIV-1 and facilitates its capture by platelets. Platelet-aggregating snake venom protein rhodocytin also binds to CLEC2.

Product Info

Amount :	100 Tests
Purification :	Purified antibody is conjugated with activated allophycocyanin (APC) under optimum conditions and unconjugated antibody and free fluorochrome are removed by size-exclusion chromatography.
Content :	Storage Buffer: Stabilizing phosphate buffered saline (PBS), pH 7.4, 15 mM sodium azide
Storage condition :	Store at 2-8°C. Protect from prolonged exposure to light. Do not freeze.

Application Note

Flow cytometry: The reagent is designed for analysis of human blood cells using 10 µl reagent / 100 µl of whole blood or 10^6 cells in a suspension. The content of a vial (1 ml) is sufficient for 100 tests.

9853 Pacific Heights Blvd.
Suite D. San Diego,
CA 92121, USA
Tel: 858-263-4982
Email: info@abeomics.com



Figure 1: Flow cytometry surface staining pattern of human peripheral whole blood stained using anti-human CLEC2 (AYP1) APC antibody (10 Î¼l reagent / 100 Î¼l of peripheral whole blood).



Figure 2: